MedTrace Logo

Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19

NCT05172180 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2024-12-19

No results posted yet for this study

Summary

Objective of the study: to investigate the effect of meglumine succinate solution on the dynamics of metabolic blood parameters and respiratory function of the lungs in intensive care patients with new coronavirus infection. An observational prospective study included 105 patients with a severe course of novel coronavirus infection

Conditions

Interventions

DRUG

Reamberin

the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)

DRUG

Ringer's solution

Ringer's solution at an average daily dose of 8.1 ml/kg/day

Sponsors & Collaborators

  • POLYSAN Scientific & Technological Pharmaceutical Company

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-01-31
Completion
2021-04-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172180 on ClinicalTrials.gov